TARGOVAX ASA - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Oslo, 14 October 2020: Reference is made to the stock exchange announcement by Targovax ASA (OSE:TRVX) ("Targovax" or the "Company"), a clinical stage biotechnology company developing oncolytic viruses to target hard-to-treat solid tumors, earlier today regarding a contemplated private placement of new shares in the Company to raise gross proceeds of up to NOK 75 million (the "Private Placement"). The Private Placement took place through an accelerated bookbuilding process after close of market today, on 14 October 2020.

The Company is pleased to announce that the Private Placement has been successfully completed, raising gross proceeds of approximately NOK 75 million through the allocation of 10,344,828 new shares (the "New Shares") at a subscription price of NOK 7.25 per Offer Share (the "Subscription Price").

Carnegie AS, DNB Markets, a part of DNB Bank ASA and Bryan, Garnier & Co Ltd. acted as joint bookrunners (the "Joint Bookrunners") in connection with the Private Placement. The Private Placement attracted strong interest from existing shareholders and new institutional investors, both in the Nordics and internationally, and the book was covered multiple times.

The net proceeds from the Private Placement and existing cash is expected to provide runway into Q1 2022 and finance the following activities: further development of the ONCOS platform (Melanoma: Part 2 clinical and immune data on all 12 patients; Colorectal: Part 1 data 13 patients (subject to sponsor timelines); Mesothelioma: 18 and 24 months survival data and Preparations for future trial(s)), CMC activities (manufacturing of clinical material for trials during the period), pipeline extension (investments in new pipeline projects; exploring mutRAS projects; Scientific support to ONCOS-102 and maintaining and building the patent portfolio) and general corporate purposes.

The Private Placement and the issuance of the New Shares was resolved by the Company's board of directors at a board meeting held on 14 October 2020, based on the authorisation granted at the Company's annual general meeting held on 29 April 2020.

Settlement of the New Shares towards investors allocated shares in the Private Placement will be made on a delivery versus payment basis on 19 October 2020 (T+2 settlement) (the "Settlement Date"), by delivery of existing and unencumbered shares in the Company that are already listed on the Oslo Stock Exchange, pursuant to share lending agreements. The New Shares delivered to the subscribers will thus be tradable from allocation. The shares borrowed for settlement of the Private Placement will be redelivered to the share lenders in the form of new shares in the Company and will be listed on the Oslo Stock Exchange upon the publication of a listing prospectus approved by the Norwegian Financial Supervisory Authority, expected to be on or about 19 October 2020.

Notification of allotment of the New Shares and payment instructions is expected to be sent to the applicants through a notification from the Joint Bookrunners on or about 15 October 2020.

Following registration of the new share capital pertaining to the Private Placement with the Norwegian Register of Business Enterprises, which is expected to take place on or about 21 October 2020, the Company will have an issued share capital of NOK 8,652,059.20, divided into 86,520,592 shares, each with a par value of NOK 0.10.

Completion of the Private Placement entails a deviation from the existing shareholders' pre-emptive rights to subscribe for and be allocated new shares and the equal treatment obligations under the Norwegian Securities Trading Act and Oslo Børs' Circular no. 2/2014, and the Board is of the opinion that the proposed Private Placement is in compliance with these requirements. The Board has carefully considered such deviation and has resolved that the Private Placement is in the best interests of the Company and its shareholders. In reaching this conclusion the board of directors has, inter alia, considered the implications of an underwritten rights issue, alternative financing sources, the dilutive effect of the share issue, the prevailing volatile market conditions, the investor interest in the transaction and development of the Company enabled by securing the new equity.

Subject to (i) the prevailing market price of the Company's shares not being lower than the Subscription Price in a period following completion of the Private Placement (to be determined by the board of directors in its sole discretion), (ii) relevant corporate resolutions being passed by the  Board, including the resolution to proceed with such offering, and (iii) the approval of a prospectus by the Norwegian Financial Supervisory Authority (the "Prospectus), the Company will carry out a subsequent offering of up to 1,500,000 new shares in the Company (the "Subsequent Offering").

The Subsequent Offering will, if implemented, be made on the basis of the Prospectus and be directed towards eligible shareholders in the Company who (i) are shareholders as of 14 October 2020, as registered in the VPS as of 16 October 2020, (ii) were not allocated New Shares in the Private Placement, (iii) did not in their capacity as larger shareholders enter into a lock-up agreement in connection with the Private Placement, and (iv) are not resident in a jurisdiction where such offering would be unlawful or, would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action (the "Eligible Shareholders"). The Eligible Shareholders will be granted non-tradable subscription rights. Over-subscription will be permitted, but subscription without subscription rights will not be permitted in the Subsequent Offering. The subscription price in the Subsequent Offering will be the same as in the Private Placement.

Advokatfirmaet Thommessen AS acts as legal advisor to the Company in connection with the Private Placement.

For further information, please contact:

Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

About Targovax

Activating the patient's immune system to fight cancer.

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax' lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "Prospectus Regulation" means Regulation (EU) 2017/1129 (together with any applicable implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intends", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The Joint Bookrunners are acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein.

Neither the Joint Bookrunners nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Joint Bookrunners nor any of their respective affiliates accepts any liability arising from the use of this announcement.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State. The Company will following the completion of the Private Placement publish a prospectus in order to have the New Shares listed on the Oslo Stock Exchange, subject to the approval of such prospectus by the Norwegian Financial Supervisory Authority. Any offering of shares in the Subsequent Offering, if any, will be made by means of a prospectus. Investors should not subscribe for any shares in the Subsequent Offering, if any, except on the basis of information contained in the aforementioned prospectus. The prospectuses will be made available at the Company's website, www.targovax.com.

Each of the Company, the Joint Bookrunners and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise.

The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.